Prognostication of patients with clear cell renal cell carcinomas based on quantification of DNA methylation levels of CpG island methylator phenotype marker genes

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Tian, Ying ^a   Arai, Eri ^a   Gotoh, Masahiro ^a   Komiyama, Motokiyo ^b   Fujimoto, Hiroyuki ^b   Kanai, Yae ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Clear cell renal cell carcinoma (ccRCC); CpG island methylator phenotype (CIMP); DNA methylation; MassARRAY system; Prognostication

Indexed keywords

PROTIRELIN; BIOLOGICAL MARKER; COTRANSPORTER; GENETIC MARKER; SLC13A5 PROTEIN, HUMAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER DIAGNOSIS; CANCER FREE SURVIVAL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; FAM150A GENE; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OVERALL SURVIVAL; PHENOTYPE; PRAC GENE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SLC13A5 GENE; SURVIVAL RATE; TRH GENE; ZNF154 GENE; ZNF540 GENE; ZNF671 GENE; CARCINOMA, RENAL CELL; GENETIC MARKER; GENETICS; KIDNEY TUMOR; MIDDLE AGED; MORTALITY; PROGNOSIS; PROMOTER REGION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BIOLOGICAL MARKERS; CARCINOMA, RENAL CELL; CPG ISLANDS; DNA METHYLATION; FEMALE; GENETIC MARKERS; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SYMPORTERS;

EID: 84929939546     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-772     Document Type: Article

References (30)

1. Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol 2011, 60:615-621.
2. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD 3rd, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS: Follow-up for clinically localized renal neoplasms: AUA guideline. J Urol 2013, 190:407-416.
3. Logan JE, Rampersaud EN, Sonn GA, Chamie K, Belldegrun AS, Pantuck AJ, Slamon DJ, Kabbinavar FF: Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol 2012, 14:65-78.
4. You JS, Jones PA: Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012, 22:9-20.
5. Baylin SB, Jones PA: A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer 2011, 11:726-734.
6. Kanai Y: Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci 2010, 101:36-45.
7. Arai E, Chiku S, Mori T, Gotoh M, Nakagawa T, Fujimoto H, Kanai Y: Single- CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis 2012, 33:1487-1493.
8. Arai E, Wakai-Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y: Genome-wide DNA methylation profiles in renal tumors of various histological subtypes and non-tumorous renal tissues. Pathobiology 2011, 78:1-9.
9. Arai E, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y: Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome. Carcinogenesis 2009, 30:214-221.
10. Arai E, Kanai Y, Ushijima S, Fujimoto H, Mukai K, Hirohashi S: Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 2006, 119:288-296.
11. Rydzanicz M, Wrzesinski T, Bluyssen HA, Wesoly J: Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications. Cancer Lett 2013, 341:111-126.
12. Issa JP: CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4:988-993.
13. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999, 96:8681-8686.
14. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez NS, Chen X, Ahmed S, Konishi K, Hamilton SR, Issa JP: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007, 104:18654-18659.
15. Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999, 59:5438-5442.
16. Morris MR, Maher ER: Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med 2010, 2:59.
17. Bibikova M, Le J, Barnes B, Saedinia-Melnyk S, Zhou L, Shen R, Gunderson KL: Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 2009, 1:177-200.
18. Eble JN, Sauter G, Epstein JI, Sesterhenn IA: Renal cell carcinoma. In World Health Organization classification of tumours. Pathology and genetics. Tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004:10-43.
19. Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982, 6:655-663.
20. Sobin LH, Wittekind C: International Union Against Cancer (UICC). TNM classification of malignant tumors. 6th edition. New York: Wiley-Liss; 2002:193-195.
21. The Cancer Genome Atlas Research Network: Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499:43-49.
22. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. 3rd edition. New York: Cold Spring Harbor Laboratory Press; 2001:6.14-6.15.
23. Clark SJ, Harrison J, Paul CL, Frommer M: High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994, 22:2990-2997.
24. Jurinke C, Denissenko MF, Oeth P, Ehrich M, van den Boom D, Cantor CR: A single nucleotide polymorphism based approach for the identification and characterization of gene expression modulation using MassARRAY. Mutat Res 2005, 573:83-95.
25. Fan J, Upadhye S, Worster A: Understanding receiver operating characteristic (ROC) curves. CJEM 2006, 8:19-20.
26. Akobeng AK: Understanding diagnostic tests 3: Receiver operating characteristic curves. Acta Paediatr 2007, 96:644-647.
27. Arai E, Kanai Y: DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status. Epigenomics 2010, 2:467-481.
28. Arai E, Sakamoto H, Ichikawa H, Totsuka H, Chiku S, Gotoh M, Mori T, Nakatani T, Ohnami S, Nakagawa T, Fujimoto H, Wang L, Aburatani H, Yoshida T, Kanai Y: Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome. Int J Cancer 2014, 135:1330-1342.
29. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, Ogawa S: Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013, 45:860-867.
30. Ziegler A, Koch A, Krockenberger K, Grosshennig A: Personalized medicine using DNA biomarkers: a review. Hum Genet 2012, 131:1627-1638.